THIOTEPA MSN 15mg powder for concentrate infusion solution medication leaflet

L01AC01 thiotepa • Antineoplastic and immunomodulating agents | Alkylating agents | Ethylene imines

Thiotepa is an alkylating agent used in the treatment of certain types of cancer, including bladder cancer, ovarian cancer, and breast cancer. It works by interfering with the DNA of cancer cells, thereby inhibiting their growth and division.

The medication is administered intravenously or intravesically, as directed by a doctor, and the dosage is adjusted based on the type of cancer and the patient's condition. It is primarily used as part of a chemotherapy regimen.

Patients should be closely monitored to detect potential side effects, such as bone marrow suppression, nausea, or liver toxicity. It is important for patients to inform their doctor of any unusual symptoms.

Common side effects include nausea, vomiting, decreased blood cell counts, and fatigue. In rare cases, severe reactions such as liver toxicity or serious infections may occur. Patients should be informed of these risks before starting treatment.

General data about THIOTEPA MSN 15mg

Substance: thiotepa

Date of last drug list: 01-10-2025

Commercial code: W71321001

Concentration: 15mg

Pharmaceutical form: powder for concentrate infusion solution

Quantity: 1

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: PHARMADOX HEALTHCARE LIMITED - MALTA

Holder: MSN LABS EUROPE LIMITED - MALTA

Number: 16190/2025/01

Shelf life: 2 years-after packing for marketing;dupa diluare-it is used immediately

Concentrations available for thiotepa

100mg, 15mg, 400mg